Mestag Therapeutics Ltd. has raised a $40 million round from existing investors as it completes final preparations for its lead program MST-312 to enter clinical development in mid-2026. MST-312 is a bispecific antibody aimed at the lympho-toxin β receptor, which is essential for the development of lymphoid tissues.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Aminex, GSK, Mineralys.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: AMC Robotics, Aptar, Firefly, Geovax, Hive Digital, Inovio, Insulet, Intuitive Surgical, Koelis, Oncopeptides, Pfizer, Prism, Receptor.AI, Vistagen.
Shares of Cytomx Therapeutics Inc. hit a new 52-week high as the company unveiled preliminary data from an ongoing phase I study of varsetatug masetecan (Varseta-M) in late-line metastatic colorectal cancer.
Multi-modality platform company Kanaph Therapeutics Inc. raised ₩40 billion (US$26.7 million) through its Kosdaq stock sale March 16, becoming the first Korean biotech to go public this year. The Seoul-based company’s shares (KOSDAQ:0082N0) climbed to ₩70,000 in intraday trading before closing at ₩50,600 – 153% higher than the offering price.
G2gbio Inc. secured a ₩20 billion (US$13.35 million) investment from Samsung Epis Holdings Co. Ltd. and a joint research and license agreement for two assets, including a long-acting obesity treatment, with subsidiary Samsung Bioepis Co. Ltd. March 16.
Amplifon SpA signed a definitive agreement with GN Store Nord A/S to acquire its entire hearing business for €2.3 billion (US$2.64 billion) on a cash-free and debt-free basis. The move by Amplifon will see it become a fully vertically integrated global player poised to transform the hearing care industry.
RSS
